+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sarepta Therapeutics - logo

Sarepta Therapeutics is a biopharmaceutical company that focuses on the development of RNA-based therapeutics for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD). It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

From
From
From
Market Spotlight: Duchenne Muscular Dystrophy (DMD) - Product Thumbnail Image

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

  • Report
  • February 2020
  • 56 Pages
From
From
Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2020 - Product Thumbnail Image

Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
Duchenne Muscular Dystrophy - Pipeline Review, H1 2020 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 381 Pages
From
Muscular Dystrophy - Pipeline Review, H2 2019 - Product Thumbnail Image

Muscular Dystrophy - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 233 Pages
From
West Nile Virus Infections Global Clinical Trials Review, H2, 2018 - Product Thumbnail Image

West Nile Virus Infections Global Clinical Trials Review, H2, 2018

  • Clinical Trials
  • September 2018
  • 37 Pages
From
From
From
From
Dystrophin - Pipeline Review, H1 2020 - Product Thumbnail Image

Dystrophin - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 122 Pages
From
Loading Indicator
adroll